Mumbai: Pathology laboratory chain, Metropolis Healthcare ended the second quarter of fiscal year 2025-26 with consolidated revenue of Rs 429 crore, up 23 per cent against the corresponding quarter.

Net profit increased by 13 per cent year-on-year (YoY) to Rs 53 crore, while Ebitda stood at Rs 109 crore.

During the July-September quarter, Metropolis’s Revenue per Patient (RPP) and Revenue per Test (RPT) increased by 11 per cent and 10 per cent YoY, respectively.

The diagnostic chain B2B business reported a growth of 33 per cent, while B2C revenue inched up 16 per cent YoY.

“We delivered consistent results this quarter, in line with our guidance, even as lower incidence of vector-borne diseases impacted seasonal demand,” said Surendran Chemmenkotil, MD, Metropolis Healthcare.

See Full Page